Cabenuva injection is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor. The ...

Simultaneous approval of VOCABRIA (cabotegravir oral tablets), for short-term treatment in conjunction with CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), also ...

People with HIV may have to take multiple medicines just to keep the virus under control. Medicines for HIV are usually taken every day, and it is crucial that people do not miss their dose or else ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, ...

(Reuters) - The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare. "This is the first ...

Last week, the FDA denied the approval of Cabenuva, the first of its kind monthly HIV injection treatment. Developers hoped that the monthly injection would replace daily pills, thus making life ...

Cabenuva (cabotegravir/rilpivirine) has potential interactions with other medications and some supplements. These interactions could affect how well the drug works or ...

After the FDA rejected its once-monthly HIV injection Cabenuva in December, GlaxoSmithKline’s keeping the talk going about its long-acting options. Now, it has rolled out detailed data showing a ...

You can save this article by registering for free here. Or sign-in if you have an account. GlaxoSmithKline’s HIV treatments division has received approval for its long-acting HIV injection from Canada ...

Add Yahoo as a preferred source to see more of our stories on Google. A GSK logo is seen on a flag at a GSK research centre in Stevenage FRANKFURT (Reuters) - GlaxoSmithKline's HIV business ViiV is ...

A kit with two injectable medicines—ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— CABENUVA was co-developed as part of a collaboration with Janssen and builds on ViiV Healthcare’s industry ...

CABENUVA allows virologically suppressed adults living with HIV to maintain viral suppression while reducing their dosing schedule from 365 days to 12 days per year. VOCABRIA and CABENUVA should not ...